GlassScriptPhysician profile
Beni T Dang
NPI 1386101665
$751.44
in general payments reported to CMS, 2019-2025
14 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $115 · 2024: $306 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.44 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $165.44 | 2024 | Urolift |
| Ethicon US, LLC | $137.10 | 2023-2024 | Stratafix, Evarrest, Ethicon |
| Janssen Biotech, INC. | $90.00 | 2025 | Erleada |
| Intuitive Surgical, INC. | $78.38 | 2023 | Da Vinci Surgical System |
| 180 Medical, INC. | $57.22 | 2025 | Cure Catheter |
| Astellas Pharma US INC | $33.71 | 2025 | Xtandi |
| Boston Scientific Corporation | $32.75 | 2024-2025 | Ams 700, Lithovue Elite |
| Astrazeneca Pharmaceuticals LP | $28.98 | 2025 | Lynparza |
| Coloplast Corp | $23.33 | 2025 | |
| Merck Sharp & Dohme LLC | $22.93 | 2025 | Keytruda |
| Ferring Pharmaceuticals INC. | $22.62 | 2025 | Adstiladrin |
| Davol INC. | $22.08 | 2023 | Phasix Mesh |
| Urogen Pharma, INC. | $20.88 | 2025 | |
| Recordati_rare_diseases_inc. | $16.02 | 2025 | Panhematin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beni Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.